MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/17588359261458324

Медицинская библиотека · Therapeutic advances in medical oncology · 2026

Current and emerging therapies targeting cell surface antigens and epigenetics in extensive stage small cell lung cancer: primer for clinicians.

Hao Zhonglin, Villano John, Arnold Susanne M, Anthony Lowell

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Extensive stage small cell lung cancer (ES-SCLC) carries a very poor prognosis and has been the focus of intensive research. Targeting cell surface molecules is paying off. Moving beyond immune checkpoint inhibitors (ICI), targeting DLL3 with tarlatamab in previously treated ES-SCLC generated an unprecedented response. Use of a combination of vascular endothelial growth factor (VEGF)/PD-1/PD-L1 antibody and chemotherapy seemed more effective than ICI plus chemotherapy. Bispecific antibodies targeting PD-1/PD-L1/VEGF in combination with chemotherapy are being tested in the first-line setting. B7H3 and SEZ6 antibody-drug conjugates yielded encouraging results in the early phase. Modulation of epigenetic processes is being pursued for its potential to reprogram cancer cells to a disadvantage for growth and immune evasion. Due to tumor heterogeneity and plasticity, rational combinations pursuing broader cancer cell vulnerabilities are likely necessary in the future to prevent relapse. Better tools for response monitoring are urgently needed to gauge progress.

Для цитирования: Hao Zhonglin, Villano John, Arnold Susanne M, Anthony Lowell. Current and emerging therapies targeting cell surface antigens and epigenetics in extensive stage small cell lung cancer: primer for clinicians.. Therapeutic advances in medical oncology. 2026. DOI: 10.1177/17588359261458324.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.